Latest news with #EmploymentInducementIncentiveAwardPlan
Yahoo
4 days ago
- Business
- Yahoo
Skillsoft Announces New Employee Inducement Grant Under NYSE Rule 303A.08
BOSTON, June 06, 2025--(BUSINESS WIRE)--Skillsoft (NYSE: SKIL) ("Skillsoft" or the "Company"), the platform that empowers organizations and learners to unlock their full potential, today announced that on June 4, 2025, the Talent and Compensation Committee of Skillsoft's Board of Directors made a grant of 50,000 restricted stock units ("RSUs") of the Company's Class A common stock to Raianne Reiss. The grant of RSUs was offered as a material inducement to Ms. Reiss' hiring as Chief Marketing Officer on April 28, 2025, and was made under Skillsoft's 2024 Employment Inducement Incentive Award Plan. 50% of such RSUs vest ratably over four years, and the remaining 50% vest at the end of a three-year period, based on the achievement of specified annual revenue growth targets, as determined by the Board of Directors, in each case, subject to Ms. Reiss' continued employment with the Company through each vesting date. The awards were granted in reliance on the employment inducement exemption under the NYSE's Listed Company Manual Rule 303A.08, which requires public announcement of inducement awards. The Company is issuing this press release pursuant to Rule 303A.08. About SkillsoftSkillsoft (NYSE: SKIL) empowers organizations and learners to unlock their full potential by delivering personalized, interactive learning experiences and enterprise-ready solutions. Powered by AI and strengthened by a broad ecosystem of partners, the Skillsoft platform helps customers solve some of today's most complex business challenges including bridging skill gaps, improving talent retention, driving digital transformation, and future-proofing the workforce. Skillsoft is the talent development partner of choice for thousands of organizations – including 60% of the Fortune 1000 – and serves a global community of more than 95 million learners. For more information, visit View source version on Contacts Investors Ross Collins or Stephen PoeSKIL@ Media Cameron
Yahoo
6 days ago
- Business
- Yahoo
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES, June 04, 2025--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 2, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 18,250 shares of Puma common stock to three new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, June 1, 2025, and one-sixth of the shares underlying the award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4). About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc. In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer. View source version on Contacts Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500info@ ir@
Yahoo
03-06-2025
- Business
- Yahoo
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the 'Company'), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees. On June 2, 2025, the Company issued to these employees options to purchase an aggregate of 26,350 shares of the Company's common stock with an exercise price of $9.98, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on June 2, 2026, and then in three equal annual installments thereafter such that the options will be fully vested on June 2, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company. About Cartesian Therapeutics Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company's lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company's clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit or follow the Company on LinkedIn or X, formerly known as Twitter. Contact Information:Investor Contact:Megan LeDucAssociate Director, Investor Media Contact:David RosenArgot in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
02-05-2025
- Business
- Globe and Mail
Cartesian Therapeutics Announces New Employment Inducement Grants
FREDERICK, Md., May 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the 'Company'), a clinical-stage biotechnology company pioneering cell therapy for the treatment of autoimmune diseases, today announced the granting of inducement awards to five new employees. On May 1, 2025, the Company issued to these employees options to purchase an aggregate of 27,700 shares of the Company's common stock with an exercise price of $12.27, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on May 1, 2026, and then in three equal annual installments thereafter such that the options will be fully vested on May 1, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company. About Cartesian Therapeutics Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company's lead asset, Descartes-08, is a CAR-T entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. A Phase 3 trial of Descartes-08 in patients with generalized myasthenia gravis has received written agreement from the FDA under the Special Protocol Assessment process. The Company's clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit or follow the Company on LinkedIn or X, formerly known as Twitter. Contact Information: Investor Contact: Megan LeDuc Associate Director, Investor Relations Media Contact: David Rosen Argot Partners
Yahoo
28-02-2025
- Business
- Yahoo
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., February 28, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 11, 2025, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units ("RSUs") representing 110,681 shares of its common stock to 102 new non-executive employees and one non-qualified stock option award to purchase 22,091 shares of its common stock to one new non-executive employee with a grant date of February 24, 2025 under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the "Inducement Plan"). The RSUs and stock options were granted as inducements material to the employees entering into employment with Guardant in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Guardant, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with Guardant, pursuant to Nasdaq Listing Rule 5635(c)(4). One-third of the shares underlying each RSU award vest on an annual basis on the anniversary of the vesting commencement date, subject to each employee's continued employment with Guardant as of each such vesting date. The RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of a RSU award agreement covering the grant. All stock options have an exercise price of $42.44 per share, which is equal to the closing price of Guardant's common stock on The Nasdaq Global Select Market on February 24, 2025. One-third of the shares underlying each stock option award vest on the one-year anniversary of the vesting commencement date and continue to vest monthly thereafter over 24 months, subject to each employee's continued employment with Guardant as of each such vesting date. The stock options are subject to the terms and conditions of the Inducement Plan and the terms and conditions of a stock option award agreement covering the grant. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. View source version on Contacts Investor Contact: Zarak Khurshidinvestors@ Media Contact: Melissa Marascopress@ +1 650-647-3711 Sign in to access your portfolio
